TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1736038

Group type: COMPARATOR
Intervention: Patients with liver disease
Number of subjects: 60

Group type: COMPARATOR
Intervention: Patients with severe malnutrition
Number of subjects: 60

Group type: COMPARATOR
Intervention: Patients with liver disease, septicemia, renal insufficiency, and those on long-term glucose feeding
Number of subjects: 60

Group type: COMPARATOR
Intervention: Overall mortality rate in study patients
Number of subjects: 60
Study: 30720733

Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Coordinative training
Number of subjects: 45

Group type: COMPARATOR
Intervention: Assisted homework sessions
Number of subjects: 45
Study: 30537982

Group type: EXPERIMENTAL
Intervention: Preoperative neurocognitive training for at least 10 days, continued for 4 weeks postoperatively
Number of subjects: 45

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 45
Study: 26195621

Group type: EXPERIMENTAL
Intervention: Torsion adapter
Number of subjects: 10

Group type: COMPARATOR
Intervention: Rigid placebo
Number of subjects: 10
Study: 25435806

Group type: EXPERIMENTAL
Intervention: FAST-guided ProSeal LMA insertion
Number of subjects: 140

Group type: COMPARATOR
Intervention: IT-assisted ProSeal LMA insertion
Number of subjects: 140
Study: 22519806

Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 19995857

Group type: EXPERIMENTAL
Intervention: Internet-based individualized training (IT)
Number of subjects: 110

Group type: COMPARATOR
Intervention: General training (GT)
Number of subjects: 110
Study: 19018087

Group type: EXPERIMENTAL
Intervention: Capecitabine plus Oxaliplatin (CAP/OX)
Number of subjects: 3494

Group type: COMPARATOR
Intervention: Infusional Fluorouracil plus Oxaliplatin (FU/OX)
Number of subjects: 3494
Study: 16283925

Group type: EXPERIMENTAL
Intervention: Bright white light treatment (8,500 Lux) for one hour a day
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Dim red light treatment (<10 Lux) for one hour a day
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo (dim red light treatment)
Number of subjects: 81
Study: 12817911

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (r‐HuEpo) treatment
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (untreated subjects)
Number of subjects: 8
Study: 10229041

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 36
Study: 8904622

Group type: EXPERIMENTAL
Intervention: Minaprine 100 mg once daily
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Minaprine 200 mg once daily
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Minaprine 300 mg once daily
Number of subjects: 531

Group type: COMPARATOR
Intervention: Amitriptyline 150 mg once daily (75 mg during the first week)
Number of subjects: 531
Study: 2011462

Group type: EXPERIMENTAL
Intervention: Randomized marker type procedure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intramodal conditions with physical characteristics of markers
Number of subjects: 0
Study: 6365016

Group type: EXPERIMENTAL
Intervention: Professionally staffed community
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Peer confrontation community
Number of subjects: 347

Group type: COMPARATOR
Intervention: Eclectic program (professionals and paraprofessionals)
Number of subjects: 347

Group type: COMPARATOR
Intervention: Withdrawal-only group
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Both successful communities
Number of subjects: 347
Study: 31340956

Group type: EXPERIMENTAL
Intervention: Integrated GP care plus treatment as usual (includes GP training in cognitive behavioural skills, GP supervision, and written/audio-visual materials for GPs and participants)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 240
Study: 29959802

Group type: EXPERIMENTAL
Intervention: SD-1077/CD
Number of subjects: 16
Study: 27223813

Group type: EXPERIMENTAL
Intervention: Oral vinorelbine plus cisplatin
Number of subjects: 151

Group type: COMPARATOR
Intervention: Pemetrexed plus cisplatin
Number of subjects: 151
Study: 24317208

Group type: EXPERIMENTAL
Intervention: Biofeedback electromyography (n = 16)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Common physiotherapy (n = 13)
Number of subjects: 29
Study: 23649826

Group type: EXPERIMENTAL
Intervention: Fecal immunochemical test (FIT)
Number of subjects: 1426
Study: 20947383

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 18536386

Group type: EXPERIMENTAL
Intervention: Xianglingwan administered from the fifth day of the menstrual cycle for 3 weeks every month for three months
Number of subjects: 54
Study: 16284750

Group type: EXPERIMENTAL
Intervention: Amphetamine administration
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 10
Study: 15023658

Group type: EXPERIMENTAL
Intervention: ALA plus CLA (3.2g CLA)
Number of subjects: 19

Group type: COMPARATOR
Intervention: ALA plus placebo (soybean oil)
Number of subjects: 19
Study: 10875786

Group type: EXPERIMENTAL
Intervention: Tuberculosis vaccine (exact details not specified)
Number of subjects: 4400

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 4400
Study: 8927950

Group type: EXPERIMENTAL
Intervention: Recombinant interferon beta‐1b
Number of subjects: 30
Study: 1740374

Group type: EXPERIMENTAL
Intervention: 1% pilocarpine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 3% pilocarpine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Tropicamide (0.4%)
Number of subjects: 36
Study: 6653131

Group type: EXPERIMENTAL
Intervention: Combination of orphenadrine (35 mg) and paracetamol (450 mg) tablets, 1 tablet 3 times daily
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 30866917

Group type: EXPERIMENTAL
Intervention: Combinatorial digital and organisational intervention combining risk stratification algorithms, practice-based quality improvement, and health monitoring and coaching.
Number of subjects: 235800

Group type: EXPERIMENTAL
Intervention: Combinatorial digital and organisational intervention
Number of subjects: 235800
Study: 30340939

Group type: EXPERIMENTAL
Intervention: Transdermal oestrogen (oestradiol hemihydrate patches)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Oral oestrogen (oestradiol valerate pills)
Number of subjects: 140
Study: 26903143

Group type: EXPERIMENTAL
Intervention: Home-based robot-guided therapy
Number of subjects: 41

Group type: COMPARATOR
Intervention: Laboratory-based robot-guided therapy
Number of subjects: 41
Study: 24825868

Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine (TIV)
Number of subjects: 796

Group type: EXPERIMENTAL
Intervention: Infection with H1N1pdm09 in 2009-2010
Number of subjects: 796

Group type: EXPERIMENTAL
Intervention: Infection with H3N2 in 2010
Number of subjects: 796
Study: 21937520

Group type: EXPERIMENTAL
Intervention: Aerobic interval training (AIT)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Usual care rehabilitation
Number of subjects: 107

Group type: COMPARATOR
Intervention: Both AIT and Usual care
Number of subjects: 107
Study: 20040875

Group type: EXPERIMENTAL
Intervention: Anti-VEGF agents
Number of subjects: 0
Study: 17324131

Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Infliximab 10 mg/kg
Number of subjects: 728

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Infliximab therapy
Number of subjects: 728
Study: 16351370

Group type: EXPERIMENTAL
Intervention: Increased attachment security through implicit and explicit priming techniques
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dispositional attachment-related anxiety and avoidance
Number of subjects: 0
Study: 12028174

Group type: EXPERIMENTAL
Intervention: Care protocol followed by community nurses for 6 months after discharge
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 89
Study: 9448170

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg b.i.d., clarithromycin 500 mg b.i.d., colloidal bismuth subcitrate 120 mg q.i.d. for 7 days
Number of subjects: 182

Group type: COMPARATOR
Intervention: Omeprazole 40 mg b.i.d., clarithromycin 500 mg b.i.d., amoxicillin 1 g b.i.d. for 7 days
Number of subjects: 182
Study: 7879787

Group type: EXPERIMENTAL
Intervention: Intervention group (not specified)
Number of subjects: 5306
Study: 2243689

Group type: EXPERIMENTAL
Intervention: Both canaliculi occluded
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Monocanalicular obstruction (either upper or lower)
Number of subjects: 20
Study: 487808

Group type: EXPERIMENTAL
Intervention: Active T‐shaped IUD releasing 65 micrograms/day of progesterone
Number of subjects: 1320

Group type: COMPARATOR
Intervention: Plain T‐shaped IUD
Number of subjects: 1320
Study: 31419353

Group type: EXPERIMENTAL
Intervention: Active treatment group (ATG, n = 13)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Passive treatment group (PTG, n = 13)
Number of subjects: 26
Study: 30635159

Group type: EXPERIMENTAL
Intervention: SBC-103 (5.0 mg/kg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: SBC-103 (10.0 mg/kg)
Number of subjects: 11
Study: 28456800

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Number of subjects: 856

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 856
Study: 25666315

Group type: EXPERIMENTAL
Intervention: Outpatient treatment
Number of subjects: 149

Group type: COMPARATOR
Intervention: Inpatient treatment
Number of subjects: 149
Study: 23640009

Group type: COMPARATOR
Intervention: Nicotine patch alone (control condition)
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Bupropion augmentation of the patch
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Varenicline alone
Number of subjects: 606
Study: 21832964

Group type: EXPERIMENTAL
Intervention: Oral sea buckthorn oil (2 g daily for 3 months)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo oil (2 g daily for 3 months)
Number of subjects: 100
Study: 19358501

Group type: EXPERIMENTAL
Intervention: Acupoint sticking therapy
Number of subjects: 66

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 66
Study: 16989377

Group type: EXPERIMENTAL
Intervention: Dry mopping and boric acid in alcohol ear drops
Number of subjects: 328

Group type: COMPARATOR
Intervention: Dry mopping alone
Number of subjects: 328

Group type: COMPARATOR
Intervention: Amoxicillin added to treatment
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Hearing test before and after treatment
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Boric acid in alcohol ear drops
Number of subjects: 328
Study: 12710223

Group type: EXPERIMENTAL
Intervention: Bimanual triangulation using crossed hand-held rods
Number of subjects: 24
Study: 12813265

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 9193323

Group type: EXPERIMENTAL
Intervention: DZR (DZR-to-doxorubicin ratio, 10:1)
Number of subjects: 534

Group type: COMPARATOR
Intervention: PLA
Number of subjects: 534
Study: 1447641

Group type: EXPERIMENTAL
Intervention: Protein hydrolysate formula
Number of subjects: 177

Group type: COMPARATOR
Intervention: Adapted cow milk formula (Control)
Number of subjects: 177
Study: 3485757

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg X d‐1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol (160 mg X d‐1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0
Study: 31410672

Group type: EXPERIMENTAL
Intervention: SRP with diode laser (940 nm)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: SRP with photodynamic therapy (670 nm)
Number of subjects: 21

Group type: COMPARATOR
Intervention: SRP alone (control group)
Number of subjects: 21
Study: 27142209

Group type: EXPERIMENTAL
Intervention: Single-port laparoscopic totally extraperitoneal (SP TEP)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Conventional laparoscopic totally extraperitoneal (CL TEP)
Number of subjects: 99
Study: 24158978

Group type: EXPERIMENTAL
Intervention: Arm ergometry, rowing, bicycle ergometry for 8-10 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 42
Study: 22752384

Group type: EXPERIMENTAL
Intervention: GSK1521498 5 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20220282

Group type: EXPERIMENTAL
Intervention: Music therapy (40 min, once a day for 8 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no music therapy)
Number of subjects: 60
Study: 19099160

Group type: EXPERIMENTAL
Intervention: Chest physiotherapy
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control
Number of subjects: 31
Study: 14677069

Group type: EXPERIMENTAL
Intervention: Group P (power athletes)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Group E (endurance athletes)
Number of subjects: 12
Study: 11390728

Group type: EXPERIMENTAL
Intervention: Vitamin C (2 g oral administration)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 9232130

Group type: EXPERIMENTAL
Intervention: Intravenous phenylephrine, 50‐200 micrograms/min, titrated to a 20% increase in mean arterial blood pressure
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO), 40 ppm
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination of phenylephrine and NO
Number of subjects: 12
Study: 8355067

Group type: EXPERIMENTAL
Intervention: Technetium-99m tetrofosmin
Number of subjects: 26

Group type: COMPARATOR
Intervention: 201Tl
Number of subjects: 26
Study: 2901302

Group type: EXPERIMENTAL
Intervention: 120 mg oral pyridostigmine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 100 micrograms i.v. GHRH (1‐29) NH2
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pyridostigmine and methionyl‐hGH
Number of subjects: 6

Group type: COMPARATOR
Intervention: Methionyl‐hGH
Number of subjects: 6
Study: 30120476

Group type: EXPERIMENTAL
Intervention: cfDNA testing followed by invasive testing only if cfDNA results are positive (n=1034)
Number of subjects: 2111

Group type: COMPARATOR
Intervention: Immediate invasive testing procedures (n=1017)
Number of subjects: 2111

Group type: EXPERIMENTAL
Intervention: cfDNA testing
Number of subjects: 2111
Study: 26810442

Group type: EXPERIMENTAL
Intervention: Energy‐dense formula (Calogen Extra, Nutricia) 30 mL distributed 3 times daily for 6 weeks
Number of subjects: 28
Study: 25262378

Group type: EXPERIMENTAL
Intervention: Mohs' micrographic surgery (MMS)
Number of subjects: 612

Group type: COMPARATOR
Intervention: Surgical excision (SE)
Number of subjects: 612
Study: 23391814

Group type: EXPERIMENTAL
Intervention: WBRT + SRS
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: WBRT + SRS + TMZ (75 mg/m(2)/day × 21 days)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: WBRT + SRS + ETN (150 mg/day)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: WBRT + SRS + TMZ
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: WBRT + SRS + ETN
Number of subjects: 126
Study: 21211299

Group type: EXPERIMENTAL
Intervention: 1% lidocaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.9% Sodium Chloride
Number of subjects: 40
Study: 18981888

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS) plus conventional medical management (CMM)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional medical management (CMM)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS) as final treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional medical management (CMM) as final treatment
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS)
Number of subjects: 100
Study: 16622435

Group type: EXPERIMENTAL
Intervention: Neoadjuvant docetaxel-cisplatin (docetaxel 85 mg m-2 on day 1, cisplatin 40 or 50 mg m-2 on days 1 and 2 for three 3-week cycles)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Neoadjuvant docetaxel-cisplatin
Number of subjects: 75
Study: 12594153

Group type: EXPERIMENTAL
Intervention: Rocuronium 10 mg mixed with sodium bicarbonate 8.4% 2 ml
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Rocuronium 10 mg mixed with fentanyl 100 micro g
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Rocuronium 10 mg mixed with lidocaine 2%
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Rocuronium 10 mg mixed with normal saline
Number of subjects: 250

Group type: COMPARATOR
Intervention: Rocuronium 10 mg alone
Number of subjects: 250
Study: 10988281

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (8 to 16 mg once daily)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (continued)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo (withdrawal of candesartan)
Number of subjects: 216
Study: 9238898

Group type: EXPERIMENTAL
Intervention: SofScale scaling gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo gel (conventional toothpaste)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-treated calculus
Number of subjects: 0
Study: 1452799

Group type: EXPERIMENTAL
Intervention: 0.2% delmopinol hydrochloride mouthrinse
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine rinse
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 12
Study: 2409850

Group type: EXPERIMENTAL
Intervention: 1 mg ketotifen orally
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 16
Study: 31539293

Group type: EXPERIMENTAL
Intervention: Exercise training combined with Virtual Reality (VR) for 12 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no physical effort or intervention)
Number of subjects: 40
Study: 30523133

Group type: EXPERIMENTAL
Intervention: Top-down therapy
Number of subjects: 400

Group type: COMPARATOR
Intervention: Accelerated step-up therapy
Number of subjects: 400
Study: 26260754

Group type: EXPERIMENTAL
Intervention: Low-volume PEG plus ascorbic acid (LV-PEG+Asc)
Number of subjects: 319

Group type: COMPARATOR
Intervention: Split dose of polyethylene glycol (SD-PEG)
Number of subjects: 319
Study: 24798668

Group type: EXPERIMENTAL
Intervention: Cervical length measurement < 30 mm
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Multivariable model including cervical length and other predictors
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Previous preterm delivery, monochorionicity, smoking, educational level, triplet pregnancy
Number of subjects: 507
Study: 22282264

Group type: EXPERIMENTAL
Intervention: New generic formulation of entecavir tablets (test)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Available branded formulation of entecavir tablets (reference)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both test and reference formulations
Number of subjects: 0
Study: 21171314

Group type: EXPERIMENTAL
Intervention: Accelerated postoperative radiotherapy (CB)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Conventional postoperative radiotherapy (C)
Number of subjects: 112
Study: 17187655

Group type: EXPERIMENTAL
Intervention: Oxybutynin transdermal system (OXY‐TDS) 3.9 mg/day for </=6 months
Number of subjects: 2878
Study: 15292314

Group type: EXPERIMENTAL
Intervention: pioglitazone (30 mg/d)
Number of subjects: 40
Study: 11133904

Group type: EXPERIMENTAL
Intervention: Oral 17beta-estradiol (approximately 3 mg/day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 9610700

Group type: EXPERIMENTAL
Intervention: Tamoxifen (40 mg daily for either 2 or 5 years)
Number of subjects: 432

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 432
Study: 7869462

Group type: EXPERIMENTAL
Intervention: Positive parental relationships
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Parental substance use problems (SUPs)
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Males reporting positive parental relationships and no parental SUPs
Number of subjects: 479
Study: 3347651

Group type: EXPERIMENTAL
Intervention: Cyclic stretching
Number of subjects: 43

Group type: COMPARATOR
Intervention: Sustained stretching
Number of subjects: 43
Study: 29351791

Group type: EXPERIMENTAL
Intervention: Electrical acupuncture
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 120
Study: 27676662

Group type: COMPARATOR
Intervention: Lidocaine 0.5% (3 mL) + Methylprednisolone (40 mg) + Saline (1 mL)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Lidocaine 0.5% (3 mL) + Methylprednisolone (40 mg) + Calcitonin (50 IU)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both groups (Lidocaine + Methylprednisolone + Saline vs. Calcitonin)
Number of subjects: 33
Study: 25078304

Group type: EXPERIMENTAL
Intervention: Daclatasvir 60 mg once daily plus asunaprevir 100 mg twice daily for 12 weeks
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Daclatasvir 60 mg once daily plus asunaprevir 100 mg twice daily for 24 weeks
Number of subjects: 307

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 307
Study: 23522987

Group type: EXPERIMENTAL
Intervention: Microfractures of the greater tuberosity during arthroscopic rotator cuff repair (Group 2)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard repair (Group 1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Microfractures of the greater tuberosity (Group 2) for large tears
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard repair (Group 1) for large tears
Number of subjects: 80
Study: 20540803

Group type: EXPERIMENTAL
Intervention: Continuous informed consent process using locally-appropriate pictorial flipchart and pre-recorded audio tapes
Number of subjects: 1146

Group type: EXPERIMENTAL
Intervention: Continuous informed consent process
Number of subjects: 1146
Study: 18391475

Group type: EXPERIMENTAL
Intervention: Flaxseed oil (10 g/d, ALA intake 5.5 g/d)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Safflower oil (placebo, 10 g/d)
Number of subjects: 42
Study: 16636028

Group type: EXPERIMENTAL
Intervention: Anesthesiologist-controlled sedation (ACS)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Patient-controlled sedation (PCS)
Number of subjects: 64
Study: 14673725

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 600 mg daily for 6 months
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group (no UDCA)
Number of subjects: 106
Study: 15532695

Group type: EXPERIMENTAL
Intervention: Homeopathic medicine (Cantharis 30c)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11